Dr. Lucas has been involved in cancer research for > 11 years and translational/clinical studies of anticancer agents for > 7 years. He has been highly trained to perform the detailed analytical and pharmacology studies required for the translational development of such agents. He also has experience performing the pharmacokinetic and pharmacodynamic analyses of drugs as part of preclinical and clinical studies. His research focuses on the development of phenotypic probes and chemical screens to translate preclinical results into clinical practice in order to create new paradigms to individualize nanoparticle and antibody-based therapies. He also leads the development of new analytical platforms to measure drugs within different cells types as part of in vivo studies. In addition, he has extensive experience with the submission of IACUC and IRB protocols and handling the regulatory process for protocols at UNC.
Andrew Lucas, MS, PharmD
Research Assistant Professor